Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HR+/HER2- Breast Cancer × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 228 Breast Neoplasms 222 Carcinoma, Non-Small-Cell Lung 192 Prostatic Neoplasms 144 Lung Neoplasms 132 Colorectal Neoplasms 130 Neoplasm Metastasis 116 Leukemia, Myeloid, Acute 104 Ovarian Neoplasms 96 Multiple Myeloma 90 Pancreatic Neoplasms 77 Melanoma 68 Endometrial Neoplasms 68 Stomach Neoplasms 64 Squamous Cell Carcinoma of Head and Neck 62 Recurrence 62 Triple Negative Breast Neoplasms 57 Lymphoma 57 Carcinoma, Hepatocellular 55 Precursor Cell Lymphoblastic Leukemia-Lymphoma 54 Uterine Cervical Neoplasms 49 Urinary Bladder Neoplasms 48 Glioblastoma 47 Brain Neoplasms 45 Carcinoma, Renal Cell 44 Sarcoma 43 Myelodysplastic Syndromes 43 Lymphoma, Non-Hodgkin 43 Lymphoma, Large B-Cell, Diffuse 42 Hematologic Neoplasms 42

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡